SUNZEN Stock Overview
Engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sunzen Biotech Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 0.32 |
| 52 Week High | RM 0.40 |
| 52 Week Low | RM 0.19 |
| Beta | 1.85 |
| 11 Month Change | -8.57% |
| 3 Month Change | -16.88% |
| 1 Year Change | 68.42% |
| 33 Year Change | 42.22% |
| 5 Year Change | 300.00% |
| Change since IPO | 71.43% |
Recent News & Updates
Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher
Aug 06
If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity
May 25Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking
May 24Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price
Apr 22Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19Recent updates
Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher
Aug 06If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity
May 25Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking
May 24Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price
Apr 22Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You
Nov 16Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?
Mar 26Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?
Dec 10
Shareholder Returns
| SUNZEN | MY Personal Products | MY Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -0.4% |
| 1Y | 68.4% | -3.0% | 13.3% |
Return vs Industry: SUNZEN exceeded the MY Personal Products industry which returned -3% over the past year.
Return vs Market: SUNZEN exceeded the MY Market which returned 13.3% over the past year.
Price Volatility
| SUNZEN volatility | |
|---|---|
| SUNZEN Average Weekly Movement | 5.0% |
| Personal Products Industry Average Movement | 4.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in MY Market | 11.5% |
| 10% least volatile stocks in MY Market | 2.8% |
Stable Share Price: SUNZEN has not had significant price volatility in the past 3 months.
Volatility Over Time: SUNZEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Yek Teo | www.sunzen.com.my |
Sunzen Biotech Berhad engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. The company provides veterinary machines, pharmaceutical, chemical products, animal health products and equipment, laboratory services, and beauty and cosmetic products. It also manufactures and sells traditional Chinese medicine, herbal health foods, beverages, and other products; trades in crude palm oil and derivative products; and manufactures, imports, trades in, exports, and sells bird’s nests and related products.
Sunzen Biotech Berhad Fundamentals Summary
| SUNZEN fundamental statistics | |
|---|---|
| Market cap | RM 228.93m |
| Earnings (TTM) | RM 6.82m |
| Revenue (TTM) | RM 98.13m |
33.6x
P/E Ratio2.3x
P/S RatioIs SUNZEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUNZEN income statement (TTM) | |
|---|---|
| Revenue | RM 98.13m |
| Cost of Revenue | RM 67.55m |
| Gross Profit | RM 30.58m |
| Other Expenses | RM 23.76m |
| Earnings | RM 6.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0095 |
| Gross Margin | 31.16% |
| Net Profit Margin | 6.95% |
| Debt/Equity Ratio | 4.8% |
How did SUNZEN perform over the long term?
See historical performance and comparison